|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khandekar S, Dive A, Munde P and Fande PZ:
Chondroblastic osteosarcoma of the left zygomatic bone: Rare case
report and review of the literature. J Oral Maxillofac Pathol.
18:281–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berner K, Johannesen TB, Berner A,
Haugland HK, Bjerkehagen B, Bøhler PJ and Bruland ØS: Time-trends
on incidence and survival in a nationwide and unselected cohort of
patients with skeletal osteosarcoma. Acta Oncol. 54:25–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berner K, Bjerkehagen B, Bruland ØS and
Berner A: Extraskeletal osteosarcoma in Norway, between 1975 and
2009, and a brief review of the literature. Anticancer Res.
35:2129–2140. 2015.PubMed/NCBI
|
|
5
|
Haddox CL, Han G, Anijar L, Binitie O,
Letson GD, Bui MM and Reed DR: Osteosarcoma in pediatric patients
and young adults: A single institution retrospective review of
presentation, therapy, and outcome. Sarcoma. 2014:4025092014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu XW, Zi Y, Xiang LB and Han TY:
Periosteal osteosarcoma: A review of clinical evidence. Int J Clin
Exp Med. 8:37–44. 2015.PubMed/NCBI
|
|
7
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and Potential Targets in Osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun X, Luo S, He Y, Shao Y, Liu C, Chen Q,
Cui S and Liu H: Screening of the miRNAs related to breast cancer
and identification of its target genes. Eur J Gynaecol Oncol.
35:696–700. 2014.PubMed/NCBI
|
|
10
|
Tiberio P, Callari M, Angeloni V, Daidone
MG and Appierto V: Challenges in using circulating miRNAs as cancer
biomarkers. Biomed Res Int. 2015:7314792015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nagaraj AB, Joseph P and DiFeo A: miRNAs
as prognostic and therapeutic tools in epithelial ovarian cancer.
Biomark Med. 9:241–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang L, Shrestha S, LaChaud G, Scott MA
and James AW: Review of microRNA in osteosarcoma and
chondrosarcoma. Med Oncol. 32:6132015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ouyang L, Liu P, Yang S, Ye S, Xu W and
Liu X: A three-plasma miRNA signature serves as novel biomarkers
for osteosarcoma. Med Oncol. 30:3402013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penna E, Orso F and Taverna D: miR-214 as
a key hub that controls cancer networks: Small player, multiple
functions. J Invest Dermatol. 135:960–969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang KC, Xi HQ, Cui JX, Shen WS, Li JY,
Wei B and Chen L: Hemolysis-free plasma miR-214 as novel biomarker
of gastric cancer and is correlated with distant metastasis. Am J
Cancer Res. 5:821–829. 2015.PubMed/NCBI
|
|
17
|
Cristóbal I, Caramés C, Madoz-Gúrpide J,
Rojo F, Aguilera O and García-Foncillas J: Downregulation of
miR-214 is specific of liver metastasis in colorectal cancer and
could play a role determining the metastatic niche. Int J
Colorectal Dis. 29:8852014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J,
Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA and Cheng
JQ: MicroRNA miR-214 regulates ovarian cancer cell stemness by
targeting p53/Nanog. J Biol Chem. 287:34970–34978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gougelet A, Pissaloux D, Besse A, Perez J,
Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in
osteosarcoma as a predictive tool for ifosfamide response. Int J
Cancer. 129:680–690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian K, Wang L, Di R, Xu J, Li G and Li Z:
Effect and mechanism of miRNA to osteosarcoma cell. Pak J Pharm
Sci. 27 Suppl 5:1657–1660. 2014.PubMed/NCBI
|
|
23
|
Zhao F, Lv J, Gan H, Li Y, Wang R, Zhang
H, Wu Q and Chen Y: MiRNA profile of osteosarcoma with CD117 and
stro-1 expression: miR-1247 functions as an onco-miRNA by targeting
MAP3K9. Int J Clin Exp Pathol. 8:1451–1458. 2015.PubMed/NCBI
|
|
24
|
Wen Z, Lei Z, Jin-An M, Xue-Zhen L,
Xing-Nan Z and Xiu-Wen D: The inhibitory role of miR-214 in
cervical cancer cells through directly targeting mitochondrial
transcription factor A (TFAM). Eur J Gynaecol Oncol. 35:676–682.
2014.PubMed/NCBI
|
|
25
|
Blagodatski A, Poteryaev D and Katanaev
VL: Targeting the Wnt pathways for therapies. Mol Cell Ther.
2:282014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagaraj AB, Joseph P, Kovalenko O, Singh
S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S and
DiFeo A: Critical role of Wnt/β-catenin signaling in driving
epithelial ovarian cancer platinum resistance. Oncotarget.
6:23720–23734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Merhi A, De Mees C, Abdo R, Victoria
Alberola J and Marini AM: Wnt/β-Catenin signaling regulates the
expression of the ammonium permease gene rhbg in human cancer
cells. PLoS One. 10:e01286832015. View Article : Google Scholar : PubMed/NCBI
|
